Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.

Luedtke RR, Mishra Y, Wang Q, Griffin SA, Bell-Horner C, Taylor M, Vangveravong S, Dillon GH, Huang RQ, Reichert DE, Mach RH.

ACS Chem Neurosci. 2012 Dec 19;3(12):1050-62. doi: 10.1021/cn300142q. Epub 2012 Oct 12.

2.

Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.

Luedtke RR, Rangel-Barajas C, Malik M, Reichert DE, Mach RH.

Curr Pharm Des. 2015;21(26):3700-24. Review.

PMID:
26205291
3.

The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Heidbreder CA, Gardner EL, Xi ZX, Thanos PK, Mugnaini M, Hagan JJ, Ashby CR Jr.

Brain Res Brain Res Rev. 2005 Jul;49(1):77-105. Review.

4.

Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design.

Keck TM, Burzynski C, Shi L, Newman AH.

Adv Pharmacol. 2014;69:267-300. doi: 10.1016/B978-0-12-420118-7.00007-X. Review.

5.

Discovery, optimization, and characterization of a novel series of dopamine D2 versus D3 receptor selective antagonists.

Xiao J, Free RB, Barnaeva E, Conroy J, Doyle T, Bryant-Genevier M, Taylor MK, Southall N, Hu X, Ferrer M, Titus S, Zheng W, Sibley DR, Marugan JJ.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Dec 25 [updated 2013 Sep 3].

6.

Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development.

Le Foll B, Wilson AA, Graff A, Boileau I, Di Ciano P.

Front Pharmacol. 2014 Jul 10;5:161. doi: 10.3389/fphar.2014.00161. eCollection 2014. Review.

7.

Dopamine D3 receptor ligands: recent advances in the control of subtype selectivity and intrinsic activity.

Boeckler F, Gmeiner P.

Biochim Biophys Acta. 2007 Apr;1768(4):871-87. Epub 2006 Dec 15. Review.

8.

GPCR functional selectivity has therapeutic impact.

Mailman RB.

Trends Pharmacol Sci. 2007 Aug;28(8):390-6. Epub 2007 Jul 13. Review.

9.

Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases.

Maramai S, Gemma S, Brogi S, Campiani G, Butini S, Stark H, Brindisi M.

Front Neurosci. 2016 Oct 5;10:451. eCollection 2016. Review.

10.

Novel, Selective, and Developable Dopamine D3 Antagonists with a Modified "Amino" Region.

Micheli F.

ChemMedChem. 2017 Apr 20. doi: 10.1002/cmdc.201700148. [Epub ahead of print] Review.

PMID:
28426179

Supplemental Content

Support Center